Ultrasound BI-RADS might need some fine-tuning

Article

Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.

Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.

Dr. Dona J. Hills and colleagues from the Queens-Long Island Medical Group in New York found that 41 cancers matched current BI-RADS 2 and 3 assignments, based on their original ultrasound descriptions. They also found that 23 of the 41 had benign or negative findings on mammography. Physicians should be suspicious about ultrasound-detected lesions with atypical features, which can cause false negatives in mammography as well, Hills said.

"If we exclude suspicious findings from the 'probably benign' category and put them into a BI-RADS 4, we might not be underestimating as many cancers as we had underestimated before," she said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.